Abstract P5-13-24: Efficacy of first line CDK4/6 inhibitors in HER2-low vs HER2-zero, hormone receptor positive, HER2 negative metastatic breast cancer
Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Pablo Tolosa(Research Institute Hospital 12 de Octubre), Luís Manso(Research Institute Hospital 12 de Octubre), Ana Maria Roncero(Hospital Universitario 12 De Octubre), Mario Martínez-López(Hospital Universitario 12 De Octubre), Estefanía Toledo(Instituto de Salud Carlos III), Ana Sánchez(Research Institute Hospital 12 de Octubre), Lucía Parrilla, Santiago Terán(Hospital Universitario 12 De Octubre), Eva Ciruelos(Hospital Universitario 12 De Octubre), Laura Lema(Hospital Universitario 12 De Octubre), Manuel Alva(Hospital Universitario 12 De Octubre)
Cited by 4
Related Papers
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
|New England Journal of Medicine|2014|751
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
|New England Journal of Medicine|2018|684
Mediterranean Diet and Invasive Breast Cancer Risk Among Women at High Cardiovascular Risk in the PREDIMED Trial
|JAMA Internal Medicine|2015|510
The Mediterranean diet, plasma metabolome, and cardiovascular disease risk
|European Heart Journal|2020|372